Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
News and updates on AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) focus on its role as a therapeutic acute wound care company centered on the RECELL System and related wound care technologies. Company news frequently highlights developments in thermal burn and trauma treatment, clinical evidence for its products, and regulatory milestones in key markets.
Investors following RCEL news can expect coverage of financial results, revenue updates, and capital structure actions such as credit agreements and equity placements, as disclosed in Form 8-K filings and press releases. AVITA Medical regularly reports quarterly and annual financial performance, adjustments to revenue outlook, and steps taken to align operating expenses with its growth priorities.
News flow also includes clinical and scientific updates. AVITA Medical has reported data presentations at medical conferences, including systematic reviews of peer-reviewed literature and real-world registry analyses supporting the RECELL System in acute wound treatment. These items describe outcomes such as reduced donor site burden, faster healing, shorter hospital stays, and favorable economic impact in burn care.
Regulatory and market access developments are another recurring theme. The company has announced CE Mark approval for RECELL GO under the EU Medical Device Regulation, regulatory clearances for RECELL in Europe, Australia, and Japan, and support from Australia’s Medical Services Advisory Committee for the use of autologous skin cell suspension prepared with RECELL in severe burns. Corporate governance updates, such as board appointments and executive transitions, are also disclosed through AVITA Medical’s news releases.
For readers tracking RCEL, this news stream provides insight into the company’s clinical progress, regulatory status, financial performance, and leadership changes, all of which shape its position in the acute wound care and medical device landscape.
AVITA Medical (NASDAQ: RCEL) appointed Cary Vance as President and Chief Executive Officer, effective April 30, 2026, after serving as Interim CEO since October 2025. The Board also named Jan Stern Reed as Chair, effective immediately. Mr. Vance will remain on the Board as an executive member.
The Board described a thorough search and credited Vance with stabilizing the business, sharpening strategic focus, and rebuilding stakeholder confidence during his interim tenure. Leadership will prioritize scaling clinical adoption of AVITA’s acute wound care platform and translating momentum into consistent performance.
AVITA Medical (NASDAQ: RCEL) announced that RECELL GO received Australia TGA certification and New Zealand WAND listing, enabling commercialization for burn and acute wound treatment in both markets. Revolution Surgical, the exclusive distributor, expects to begin commercial launch within weeks. The system automates and standardizes RECELL Spray-On Skin preparation, which the company says reduces manual steps and clinical burden.
AVITA Medical (NASDAQ: RCEL) will report its first quarter 2026 financial results after U.S. market close on Thursday, May 14, 2026. A conference call and webcast will be held at 1:30 p.m. PT (May 15, 2026, 6:30 a.m. AEST) to discuss results and business highlights. Replay will be available on the company's investor relations Events page.
AVITA Medical (NASDAQ: RCEL) announced that founder Professor Fiona Wood received the American Burn Association Lifetime Achievement Award on April 15, 2026.
The award recognizes her pioneering development of spray-on skin technology commercialized as RECELL, more than 30 years of leadership in burn care, and global influence on clinical practice.
AVITA Medical (NASDAQ: RCEL) reported positive interim Cohealyx-I results showing a mean time to skin graft of 13.6 days versus a 33.2-day literature benchmark (~20-day reduction) with statistical superiority (p<0.001).
The 40-patient interim analysis showed a median time to graft of 11 days, grafting as early as 5 days, 72% grafted within 14 days, and 90% investigator satisfaction; full dataset expected in 2026.
AVITA Medical (NASDAQ: RCEL) secured a 10-year agreement with BARDA under Project BioShield, valued at up to $25.5 million to strengthen U.S. burn mass casualty preparedness. The contract provides BARDA access to 3,000 RECELL units over the term, plus procurement options and readiness support.
Approximately $3.97 million is expected as access-maintenance and readiness fee revenue over 10 years; remaining value reflects optional procurements BARDA may exercise.
AVITA Medical (NASDAQ: RCEL) will present new clinical and case data at the American Burn Association (ABA) 2026 meeting on April 7, 2026, including an interim analysis from the ongoing Cohealyx‑I multi‑center study and investigator‑led real‑world RECELL and PermeaDerm findings. The company will feature 19 presentations and 3 company‑sponsored events, highlighting potential reductions in hospital length of stay and resource use.
The exhibit theme is Healing at the Speed of Life™, emphasizing recovery outcomes beyond wound closure.
AVITA Medical (NASDAQ: RCEL) said interim CEO Cary Vance and CFO David O’Toole will present at the TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 at 8:10 a.m. PT / 11:10 a.m. ET.
A live and archived webcast will be available via the company’s Events & Presentations page at its investor website.
AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on Feb 18, 2026 at 2:00 PM PST (Feb 19, 2026 at 9:00 AM AEDT).
Interim CEO Cary Vance and CFO David O’Toole will review fourth-quarter and full-year 2025 financial and business results, followed by a Q&A. A replay will be posted on the company investor site.
AVITA Medical (NASDAQ: RCEL) reported Q4 2025 revenue of $17.6M and full-year revenue of $71.6M (+11% YoY). Q4 net loss was $11.6M (loss of $0.38/share); FY net loss was $48.6M (loss of $1.74/share). Gross margin was 82.1% for the year and cash plus marketable securities ended Q4 at $18.2M. The company closed a five-year credit facility providing up to $60M (initial $50M funded). 2026 revenue guidance: $80–85M.
Management highlighted improved cash efficiency, stabilization of reimbursement after MAC actions, ongoing clinical study enrollment, and execution-focused priorities for 2026.